Churg-Strauss syndrome (CSS) in a patient receiving pranlukast

Clin Rheumatol. 2003 Dec;22(6):491-2. doi: 10.1007/s10067-003-0791-5. Epub 2003 Nov 4.


Pranlukast is a cysteinyl leukotriene receptor I antagonist (LTRAs) approved for treatment of asthma in Japan since 1995. Compared to other LTRAs, such as zafilukast and montelukast, only few cases with Churg-Strauss syndrome (CSS) have been reported in association with treatment with pranlukast. We describe a 17-year-old Japanese male patient who developed CSS with a 13 month history of mild asthma receiving pranlukast for 11 months without systemic and/or inhaled corticosteroid administration prior to development of CSS. From the aspect of temporal relationship between treatment with pranlukast and development of CSS, a direct induction of CSS by pranlukast is suggested in our case.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Adrenal Cortex Hormones / administration & dosage
  • Asthma / diagnosis
  • Asthma / drug therapy*
  • Chromones / administration & dosage
  • Chromones / adverse effects*
  • Churg-Strauss Syndrome / chemically induced*
  • Churg-Strauss Syndrome / diagnosis*
  • Churg-Strauss Syndrome / drug therapy
  • Cyclophosphamide / administration & dosage
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Follow-Up Studies
  • Humans
  • Male
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome


  • Adrenal Cortex Hormones
  • Chromones
  • Cyclophosphamide
  • pranlukast